Abstract
Background Immune protection following either vaccination or infection with SARS-CoV-2 decreases over time.
Objective To determine the kinetics of SARS-CoV-2 IgG antibodies following administration of two doses of BNT162b2 vaccine, or SARS-CoV-2 infection in unvaccinated individuals.
Methods Antibody titers were measured between January 31, 2021, and July 31, 2021 in two mutually exclusive groups: i) vaccinated individuals who received two doses of BNT162b2 vaccine and had no history of previous infection with COVID-19 and ii) SARS-CoV-2 convalescents who had not received the vaccine.
Results A total of 2,653 individuals fully vaccinated by two doses of vaccine during the study period and 4,361 convalescent patients were included. Higher SARS-CoV-2 IgG antibody titers were observed in vaccinated individuals (median 1581 AU/mL IQR [533.8-5644.6]) after the second vaccination, than in convalescent individuals (median 355.3 AU/mL IQR [141.2-998.7]; p<0.001). In vaccinated subjects, antibody titers decreased by up to 40% each subsequent month while in convalescents they decreased by less than 5% per month. Six months after BNT162b2 vaccination 16.1% subjects had antibody levels below the seropositivity threshold of <50 AU/mL, while only 10.8% of convalescent patients were below <50 AU/mL threshold after 9 months from SARS-CoV-2 infection.
Conclusions This study demonstrates individuals who received the Pfizer-BioNTech mRNA vaccine have different kinetics of antibody levels compared to patients who had been infected with the SARS-CoV-2 virus, with higher initial levels but a much faster exponential decrease in the first group.
Funding This research was internally funded by Leumit Health Services (LHS) and was supported in part by the Intramural Research Program, National Institutes of Health, National Cancer Institute, Center for Cancer Research.
The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.
Impact statement Large scale study display the kinetics of SARS-CoV-2 IgG antibodies present in individuals vaccinated with two doses of mRNA vaccine vs. unvaccinated patients who had recovered from the disease: initial levels of antibody are much higher in vaccinated patients, but decrease faster.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was internally funded by Leumit Health Services (LHS) and was supported in part by the Intramural Research Program, National Institutes of Health, National Cancer Institute, Center for Cancer Research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by Shamir Medical Center Institutional Review Board (129-2-LEU).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
(e-mail: dr.ariel.israel{at}gmail.com), (e-mail: yshenhar{at}leumit.co.il), (e-mail: igreen{at}leumit.co.il), (e-mail: emarzon{at}leumit.co.il), (e-mail: agolanchoen{at}leumit.co.il), (e-mail: alejandro.schaffer{at}nih.gov), (e-mail: eytan.ruppin{at}nih.gov), (e-mail: svinker{at}leumit.co.il), (e-mail: allergologycom{at}gmail.com)
Conflict of Interest disclosure statement: All authors have no conflicts to disclose
Data Availability
Data were obtained from patients' electronic health records, and IRB approval restrains its use to researchers inside Leumit Health Services.
Abbreviations
- COVID-19
- Coronavirus disease of 2019
- SARS-CoV-2
- Severe acute respiratory syndrome coronavirus 2
- mRNA
- Messenger RNA
- LHS
- Leumit Health Services
- HMO
- Health maintenance organization
- SES
- Socio-economic status
- BMI
- Body mass Index
- IQR
- Interquartile range
- RT-PCR
- Reverse transcription polymerase chain reaction
- IgG
- Immunoglobulin G
- BMPCs
- Bone marrow plasma cells
- ACE2
- Angiotensin-converting enzyme 2
